mUlticenter, single-arM, open-laBel, long-teRm safety study with macitEntan in patients with puLmonary hypertension previousLy treated with mAcitentan in clinical studies
Latest Information Update: 25 Mar 2024
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Acronyms UMBRELLA
- Sponsors Actelion Pharmaceuticals
- 01 Feb 2024 Status changed from active, no longer recruiting to completed.
- 10 Oct 2023 Planned End Date changed from 13 Oct 2023 to 20 Dec 2023.
- 10 Oct 2023 Planned primary completion date changed from 12 Sep 2023 to 20 Dec 2023.